The Technical Field "受容体" had 1,049 patent application filings in the most recent period (2022-01-01 to 2022-09-30). This is a significantly decreased of -914 filings (-46.6%) over 1,963 they had in the same period of the previous year (2021-01-01 to 2021-09-30). This report also includes technical terms related to " 受容器 ", " 摂受体 ", " 摂受器 ", " リセプタ ", " リセプター ", " レセプタ ", " レセプター " in the search set.
The highest number of filings in 2018 with 3,186 cases, and their lowest number in 2022 with 1,083 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 12,343 cases in total) is 2,057, and the median is 2,562. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 2,057 patents |
Std Dev | 1,116 |
COV | 0.5 |
The number of filings has been decreasing for the last 3 years (2020 to 2023).
Year | Cases | YOY |
---|---|---|
2022 year | 1,083 cases | -58.6 % |
2021 year | 2,617 cases | +4.35 % |
2020 year | 2,508 cases | -13.46 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for 受容体 for the period of the last 10 years (2014-01-01 to 2024-05-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of 受容体, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of 受容体 over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
This patent analysis report was created for a patent search set of 23,977 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 受容体 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Comparing the number of applications of each company, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 14 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 14 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 14 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 14 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 13 cases |
ノバルティスアーゲー | 7 cases |
エフホフマン-ラロシュアーゲー | 4 cases |
武田薬品工業株式会社 | 3 cases |
ブリストル-マイヤーズスクイブカンパニー | 1 cases |
Comparing the number of applications of each company, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 416 cases, followed by リジェネロン・ファーマシューティカルズ・インコーポレイテッド with 319 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 416 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 319 cases |
ジェネンテックインコーポレイテッド | 265 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 254 cases |
ブリストル-マイヤーズスクイブカンパニー | 239 cases |
エフホフマン-ラロシュアーゲー | 186 cases |
武田薬品工業株式会社 | 146 cases |
メルク・シャープ・アンド・ドーム・コーポレーション | 62 cases |
グラクソグループリミテッド | 10 cases |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 5 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as 受容体 are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Among the top coapplicants, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 14 cases, followed by ザリージェンツオブザユニバーシティオブカリフォルニア with 13 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 14 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 13 cases |
ノバルティスアーゲー | 7 cases |
エフホフマン-ラロシュアーゲー | 4 cases |
武田薬品工業株式会社 | 3 cases |
ブリストル-マイヤーズスクイブカンパニー | 1 cases |
Among the top coapplicants, ノバルティスアーゲー has the highest number of joint applications in the last for the target period (2014 to 2024) with 416 cases, followed by ジェネンテックインコーポレイテッド with 265 cases.
Name | Cases |
---|---|
ノバルティスアーゲー | 416 cases |
ジェネンテックインコーポレイテッド | 265 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 254 cases |
ブリストル-マイヤーズスクイブカンパニー | 239 cases |
エフホフマン-ラロシュアーゲー | 186 cases |
武田薬品工業株式会社 | 146 cases |
Below is a ranking of the number of JP patent applications by 受容体’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by 受容体’s top 7 coapplicants over the last 20 years.
受容体 filed 416 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 140 cases in total) is 23.3, and the median is 22.0. The coefficient of variation (standard deviation/mean) is 0.8, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2016 with 79 cases, and their lowest number in 2022 with 7 cases.
Index | Value |
---|---|
Average | 23.3 patents |
Std Dev | 18.4 |
COV | 0.8 |
Year | Cases | YOY |
---|---|---|
2022 year | 7 cases | -63.2 % |
2021 year | 19 cases | -24.00 % |
2020 year | 25 cases | -21.88 % |
受容体 filed 186 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 62 cases in total) is 10.3, and the median is 7.0. The coefficient of variation (standard deviation/mean) is 0.8, and there have been relatively large fluctuations in the number of filings from year to year.
The highest number of filings in 2015 with 44 cases, and their lowest number in 2022 with 4 cases.
Index | Value |
---|---|
Average | 10.3 patents |
Std Dev | 8.7 |
COV | 0.8 |
Year | Cases | YOY |
---|---|---|
2022 year | 4 cases | -20.00 % |
2021 year | 5 cases | -44.4 % |
2020 year | 9 cases | -59.1 % |
受容体 filed 146 joint applications with 武田薬品工業株式会社 for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 82 cases in total) is 13.7, and the median is 13.0. The coefficient of variation (standard deviation/mean) is 0.8, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2018 with 28 cases, and their lowest number in 2022 with 3 cases.
Index | Value |
---|---|
Average | 13.7 patents |
Std Dev | 10.3 |
COV | 0.8 |
Year | Cases | YOY |
---|---|---|
2022 year | 3 cases | -76.9 % |
2021 year | 13 cases | 0 |
2020 year | 13 cases | -48.0 % |
受容体 filed 265 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 88 cases in total) is 14.7, and the median is 17.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 62 cases, and their lowest number in 2020 with 6 cases.
Index | Value |
---|---|
Average | 14.7 patents |
Std Dev | 9.1 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 14 cases | -44.0 % |
2021 year | 25 cases | +317 % |
2020 year | 6 cases | -73.9 % |
受容体 filed 254 joint applications with ザリージェンツオブザユニバーシティオブカリフォルニア for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 142 cases in total) is 23.7, and the median is 26.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2016 with 39 cases, and their lowest number in 2022 with 13 cases.
Index | Value |
---|---|
Average | 23.7 patents |
Std Dev | 13.6 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 13 cases | -53.6 % |
2021 year | 28 cases | -24.32 % |
2020 year | 37 cases | +48.0 % |
The following shows JP patents held by 受容体 that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and 受容体’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which 受容体 is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2021-06-01 ~ 2024-05-31), there were 6 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.0 times. The most recently Invalidation Trial patent is 特許7185426 "S1P受容体モジュレーターの投与計画" (Invalidation Trial day 2023-07-10) , next is 特許6931019 "多発性硬化症を処置するためのS1P受容体モジュレーター" (Invalidation Trial day 2023-06-30) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許7185426 | S1P受容体モジュレーターの投与計画 | 2023-07-10 |
2 | 特許6931019 | 多発性硬化症を処置するためのS1P受容体モジュレーター | 2023-06-30 |
3 | 特許7016341 | PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法 | 2023-03-27 |
4 | 特許6278598 | 細胞傷害誘導治療剤 | 2022-03-31 |
5 | 特許6773929 | 細胞傷害誘導治療剤 | 2022-03-31 |
6 | 特許6738314 | BCMAおよびCD3に対する結合分子 | 2021-07-02 |
Of the patent applications filed in the last 10 years (2014-06-01 to 2024-05-31), 4 patents/patent applications were invalidation trial more than once in the examination process of other patent applications. The mean of the number of invalidation trial is 1.2. The most invalidation trial patent is 特許5906333 "プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質" (2 times) , and the next most invalidation trial patent is 特許7016341 "PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法" (1 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許5906333 | プロタンパク質コンベルターゼスブチリシンケクシン9型(PCSK9)に対する抗原結合タンパク質 | 2 times |
2 | 特許7016341 | PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法 | 1 times |
3 | 特許6417431 | 複数分子の抗原に繰り返し結合する抗原結合分子 | 1 times |
4 | 特許6293103 | 自己緩衝タンパク質製剤 | 1 times |
In the last 3 years (2021-06-01 ~ 2024-05-31), there were 12 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7289655 "PAMPS及びDAMPSの除去への血液適合性多孔性ポリマービーズ吸着剤の使用" (Opposition day 2023-12-12) , next is 特許7210036 "アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法" (Opposition day 2023-07-20) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7289655 | PAMPS及びDAMPSの除去への血液適合性多孔性ポリマービーズ吸着剤の使用 | 2023-12-12 |
2 | 特許7210036 | アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法 | 2023-07-20 |
3 | 特許7188087 | 一本鎖オリゴヌクレオチド | 2023-06-12 |
4 | 特許7094269 | アンバーグリスノートを呈する香料素材のスクリーニング方法 | 2022-11-11 |
5 | 特許6988481 | 一本鎖オリゴヌクレオチド | 2022-07-04 |
6 | 特許6933898 | 養子細胞治療製品を製造するための誘導多能性幹細胞の適用 | 2022-03-07 |
7 | 特許6895380 | 治療免疫細胞の有効性を改良するための方法 | 2021-12-28 |
8 | 特許6948072 | CD8陽性T細胞を誘導する方法 | 2021-12-27 |
9 | 特許6942466 | 抗原特異的T細胞受容体遺伝子を有する多能性幹細胞の製造方法 | 2021-12-27 |
10 | 特許6846577 | 新規リパーゼ及びその用途 | 2021-09-22 |
In the last 3 years (2021-06-01 ~ 2024-05-31), there were 42 patents Protest from third parties. The average number of Protest is 1.2 times. The most recently Protest patent is 特表2022-546204 "苦味受容体ブロッカー及びその同定方法" (Protest day 2024-02-22) , next is 特開2023-171429 "新規リパーゼ及びその用途" (Protest day 2024-02-21) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特表2022-546204 | 苦味受容体ブロッカー及びその同定方法 | 2024-02-22 |
2 | 特開2023-171429 | 新規リパーゼ及びその用途 | 2024-02-21 |
3 | 特開2022-187349 | 含硫化合物臭の抑制剤の探索方法 | 2024-02-17 |
4 | 特開2023-052694 | 悪臭調節化合物の同定方法 | 2024-02-17 |
5 | 特開2023-174085 | アンモニア臭の抑制剤の探索方法 | 2024-02-17 |
6 | 特開2023-055917 | PAMPS及びDAMPSの除去への血液適合性多孔性ポリマービーズ吸着剤の使用 | 2024-01-17 |
7 | 特開2020-114266 | IgG Fcドメインを有する融合タンパク質の生産方法 | 2023-10-30 |
8 | 特許7438604 | SARS-COV-2 mRNAドメインワクチン | 2023-10-27 |
9 | 特表2021-520189 | プレバイオティック組成物及びその製造方法 | 2023-09-07 |
10 | 特開2023-098949 | 多発性硬化症を処置するためのS1P受容体モジュレーター | 2023-08-28 |
11 | 特開2023-093482 | S1P受容体モジュレーターの投与計画 | 2023-08-28 |
12 | 特開2023-039448 | がんを治療するための、PD-1アンタゴニスト及びVEGFR/FGFR/RETチロシンキナーゼ阻害剤の組合せ | 2023-07-12 |
13 | 特開2023-025012 | 難治性ホジキンリンパ腫におけるニボルマブでのPD-1遮断 | 2023-04-27 |
14 | 特許7491491 | てんかんの治療に使用するための組成物 | 2023-04-03 |
15 | 特開2021-050215 | 皮下投与される抗IL−6受容体抗体 | 2023-03-30 |
16 | 特表2021-525522 | シアリル化糖の発酵産生 | 2023-02-17 |
17 | 特開2022-188071 | 腫瘍を処置する方法において使用するための抗PD-1抗体 | 2023-02-17 |
18 | 特許7391304 | 風車の耐雷装置 | 2022-12-15 |
19 | 特開2022-058698 | 抗PD-1抗体と他の抗癌剤の組合せを使用する腎癌の処置 | 2022-10-07 |
20 | 再公表2019/189898 | 甘味受容体(T1R2/T1R3)以外も甘味応答せしめる甘味組成物 | 2022-10-07 |
Of the patent applications filed in the last 10 years (2014-06-01 to 2024-05-31), 76 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.3. The most protest patent is 特開2017-061467 "血管新生眼疾患を処置するためのVEGFアンタゴニストの使用" (5 times) , and the next most protest patent is 特開2019-167366 "血管新生眼疾患を処置するためのVEGFアンタゴニストの使用" (4 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2017-061467 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 5 times |
2 | 特開2019-167366 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 4 times |
3 | 特開2020-114266 | IgG Fcドメインを有する融合タンパク質の生産方法 | 4 times |
4 | 特開2021-020944 | 基礎代謝亢進剤 | 2 times |
5 | 特許7152399 | 悪臭中和剤を同定するための方法 | 2 times |
In the last 3 years (2021-06-01 ~ 2024-05-31), there were 466 patents Inspection from third parties. The average number of Inspection is 1.5 times. The most recently Inspection patent is 特許7486437 "免疫性血小板減少症を治療する組成物及び方法" (Inspection day 2024-04-17) , next is 特表2021-525362 "多発性骨髄腫を治療すること及び4−(4−(4−(((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−4−イル)オキシ)メチル)ベンジル)ピペラジン−1−イル)−3−フルオロベンゾニトリルのバイオマーカーの使用" (Inspection day 2024-04-12) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特許7486437 | 免疫性血小板減少症を治療する組成物及び方法 | 2024-04-17 |
2 | 特表2021-525362 | 多発性骨髄腫を治療すること及び4−(4−(4−(((2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−4−イル)オキシ)メチル)ベンジル)ピペラジン−1−イル)−3−フルオロベンゾニトリルのバイオマーカーの使用 | 2024-04-12 |
3 | 特表2022-501338 | 抗腫瘍剤としてのキナゾリン誘導体 | 2024-04-05 |
4 | 特表2021-502101 | 修飾されたリガンド依存性イオンチャネルおよび使用の方法 | 2024-04-02 |
5 | 特開2022-065089 | ジフテリア毒素-インターロイキン-3コンジュゲートに基づく方法及び組成物 | 2024-04-01 |
6 | 特表2021-521110 | 抗NRP2抗体を含む組成物及び方法 | 2024-03-29 |
7 | 特許5185443 | 生体組織から分離できる多能性幹細胞画分 | 2024-03-29 |
8 | 特表2023-532569 | 抗腫瘍壊死因子受容体抗体(抗TNFR2抗体)及びその使用 | 2024-03-28 |
9 | 特許5752671 | VEGFアンタゴニスト製剤 | 2024-03-28 |
10 | 特表2023-527884 | 異常な血管新生を治療するための局所眼科用組成物および方法 | 2024-03-28 |
11 | 特許5376573 | VEGFアンタゴニスト製剤 | 2024-03-28 |
12 | 特表2024-511695 | 局所眼科用組成物 | 2024-03-28 |
13 | 特表2021-505168 | 操作されたT細胞の組成物を製造するための方法 | 2024-03-26 |
14 | 特開2019-011372 | インターロイキン−6関連疾患の治療方法 | 2024-03-26 |
15 | 特表2024-514101 | IL-13RA2キメラ抗原受容体および使用方法 | 2024-03-26 |
16 | 特表2020-506708 | CO2および他のC1基質の、ビーガン栄養素、肥料、バイオスティミュラント、および土壌炭素隔離の加速のためのシステムへの微生物変換 | 2024-03-19 |
17 | 特表2021-516049 | 組換えT細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 | 2024-03-19 |
18 | 特開2022-187349 | 含硫化合物臭の抑制剤の探索方法 | 2024-03-14 |
19 | 特開2023-174085 | アンモニア臭の抑制剤の探索方法 | 2024-03-14 |
20 | 特表2021-529821 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 | 2024-03-13 |
Of the patent applications filed in the last 10 years (2014-06-01 to 2024-05-31), 769 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.2. The most inspection patent is 特許6320473 "アロNKT細胞を用いた免疫療法およびそのためのT細胞抗原受容体(TCR)遺伝子のα鎖領域が均一なVα−Jαに再構成されている細胞および該細胞由来NKT細胞のバンキング" (48 times) , and the next most inspection patent is 特開2019-167366 "血管新生眼疾患を処置するためのVEGFアンタゴニストの使用" (10 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6320473 | アロNKT細胞を用いた免疫療法およびそのためのT細胞抗原受容体(TCR)遺伝子のα鎖領域が均一なVα−Jαに再構成されている細胞および該細胞由来NKT細胞のバンキング | 48 times |
2 | 特開2019-167366 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 10 times |
3 | 特開2017-061467 | 血管新生眼疾患を処置するためのVEGFアンタゴニストの使用 | 8 times |
4 | 特開2019-011372 | インターロイキン−6関連疾患の治療方法 | 6 times |
5 | 特開2016-155809 | 狭窄病変および血栓溶解療法のための剪断による制御放出 | 5 times |
Of the patent applications filed in the last 10 years (2014-06-01 to 2024-05-31), 3,340 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.2. The most cited patent is 特開2016-035646 "触覚装置、および、それを有する触覚ディスプレイ" (47 times) , and the next most cited patent is 特許6082447 "複数分子の抗原に繰り返し結合する抗原結合分子" (30 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2016-035646 | 触覚装置、および、それを有する触覚ディスプレイ | 47 times |
2 | 特許6082447 | 複数分子の抗原に繰り返し結合する抗原結合分子 | 30 times |
3 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 29 times |
4 | 特許6738728 | 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用 | 23 times |
5 | 特許6345800 | 抗体−フィノマー複合体 | 22 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International